The Life Sciences Report
Notable Quotes
"We feel RXII has largely been ignored by investors, but has potential." (7/10/14) RXi Pharmaceuticals Corp. - The Life Sciences Report Interview with Reni Benjamin More >
"Shiseido's investment in a collaboration with RP is a form of validation for the company." (7/17/14) RepliCel Life Sciences Inc. - The Life Sciences Report interview with Alan Leong More >
"INO's stock could hit double digits pretty easily, in terms of its trading range, with a good outcome from the Phase 2 VGX-3100 study." (6/26/14) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Charles Duncan More >
"We believe BLU has a higher probability of success in its current Phase 3 Kiacta study." (6/12/14) BELLUS Health Inc. - The Life Sciences Report interview with Brian Bloom More >
"TRX is my favorite specialty pharmaceutical company right now, based on its valuation." (6/12/14) Tribute Pharmaceuticals Canada Inc. - The Life Sciences Report interview with Brian Bloom More >
Companies
| Last: | |||
| Change: | Change(%): | ||
| Volume: | Open: | ||
| High: | Low: | ||
| 52Wk High: | 52Wk Low: | ||
Valeant Pharmaceuticals International Inc.TICKER: VRX:NYSE; VRX:TSX
|
A summary of Expert Comments about Valeant Pharmaceuticals International Inc. is currently unavailable. You can find Expert Comments on companies similar to Valeant Pharmaceuticals International Inc. by clicking on the links below.